Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease

Abstract

Infliximab (IFX) is very effective in active inflammatory bowel disease (IBD) but up to nearly 50%[1][1] of patients will lose response or experience attenuated response to IFX due to fluctuating drug levels or formation of antibodies to IFX (ATI). There is growing evidence of the efficacy of